Health Affairs, 24, no. 3 (2005): 697-700 doi: 10.1377/hlthaff.24.3.697 © 2005 by Project HOPE	New Online   Pay Cuts For Medicare Docs   Access To Care Woes   Public Coverage More Efficient   Empowering Consumers

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Grabowski, H. Search for Related Content PubMed PubMed Citation Articles by Grabowski, H. Related Collections Consumer Issues Health Promotion/Disease Prevention International Issues Vaccines Public Health Research And Technology

Financing

PERSPECTIVE

Encouraging The Development Of New Vaccines

Investment in the development of new vaccines is suboptimal. Changing this situation requires a creative blend of "push" and "pull" strategies. One successful policy model is the Orphan Drug Act, whose key features include large research and development (R&D) tax credits as well as Food and Drug Administration (FDA) counseling and priority review. Such supply-side R&D incentive provisions can be combined with demand-side mandates and vouchers to encourage development of new vaccines. Guaranteed-purchase funds and other pull mechanisms are useful supplementary incentives in the cases of vaccines for bioterrorism and neglected diseases of poverty.

                      What's this?

This article has been cited by other articles:

				D. B. Ridley, H. G. Grabowski, and J. L. Moe Developing drugs for developing countries. Health Aff., March 1, 2006; 25(2): 313 - 324. [Abstract] [Full Text] [PDF]